Please try another search
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Steven H. Holtzman | 67 | 2014 | Independent Non Executive Director |
Patrick Amstutz | 46 | 2004 | Co-Founder, CEO, Member of Management Board & Director |
Dominik Hochli | 54 | 2021 | Independent Director |
Agnete B. Fredriksen | 44 | 2021 | Independent Director |
Michael J. Vasconcelles | 58 | 2020 | Independent Director |
Sandip S. Kapadia | 51 | 2020 | Independent Director |
William A. M. Burns | 72 | 2017 | Independent Chairman of the Board |
Vito J. Palombella | 58 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review